Genentech (RHHBY) Receives FDA Breakthrough Therapy Designation for Actemra as Giant Cell Arteritis Treatment
Go back to Genentech (RHHBY) Receives FDA Breakthrough Therapy Designation for Actemra as Giant Cell Arteritis Treatment| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 30.05 -0.03 (0.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.08 | 52 Week High | $35.13 | |||
| Open | $30.17 | 52 Week Low | $28.10 | |||
| Day High | $30.19 | P/E | N/A | |||
| Day Low | $29.95 | EPS | $0.00 | |||
| Volume | 2,077,747 | |||||
